Charlene Wu

1.2k total citations
36 papers, 841 citations indexed

About

Charlene Wu is a scholar working on Molecular Biology, Health, Toxicology and Mutagenesis and Immunology. According to data from OpenAlex, Charlene Wu has authored 36 papers receiving a total of 841 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 13 papers in Health, Toxicology and Mutagenesis and 6 papers in Immunology. Recurrent topics in Charlene Wu's work include Air Quality and Health Impacts (6 papers), Effects and risks of endocrine disrupting chemicals (5 papers) and Protein Tyrosine Phosphatases (5 papers). Charlene Wu is often cited by papers focused on Air Quality and Health Impacts (6 papers), Effects and risks of endocrine disrupting chemicals (5 papers) and Protein Tyrosine Phosphatases (5 papers). Charlene Wu collaborates with scholars based in Taiwan, United States and United Kingdom. Charlene Wu's co-authors include Paul T. Massa, Ta‐Chen Su, Fung‐Chang Sung, Chien‐Yu Lin, Kuen‐Yuh Wu, Cynthia L. Burns-Kurtis, Stephen A. Douglas, David J. Behm, Keith W. Jarosinski and Nicholas J. Laping and has published in prestigious journals such as PLoS ONE, The Science of The Total Environment and Analytical Biochemistry.

In The Last Decade

Charlene Wu

35 papers receiving 832 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Charlene Wu Taiwan 17 276 221 133 102 96 36 841
Jennifer C. Schroeder United States 7 361 1.3× 205 0.9× 183 1.4× 56 0.5× 27 0.3× 8 1.1k
Ofer Spiegelstein United States 19 305 1.1× 74 0.3× 64 0.5× 89 0.9× 70 0.7× 60 1.2k
Brett C. DiNatale United States 11 429 1.6× 298 1.3× 274 2.1× 82 0.8× 46 0.5× 12 1.3k
Victoria Wong United States 15 379 1.4× 236 1.1× 76 0.6× 76 0.7× 117 1.2× 23 1.0k
Michèle Garlatti France 20 436 1.6× 357 1.6× 89 0.7× 112 1.1× 107 1.1× 30 1.1k
Mariel Núñez Argentina 17 301 1.1× 202 0.9× 163 1.2× 80 0.8× 46 0.5× 32 869
Jay M. Wendling United States 11 299 1.1× 138 0.6× 112 0.8× 33 0.3× 48 0.5× 18 714
Ediz Demirpençe Türkiye 18 289 1.0× 120 0.5× 60 0.5× 196 1.9× 60 0.6× 38 889
Xinhua Liu China 19 305 1.1× 260 1.2× 49 0.4× 217 2.1× 29 0.3× 51 1.3k
Shoei Yn Lin‐Shiau Taiwan 13 372 1.3× 179 0.8× 107 0.8× 29 0.3× 72 0.8× 21 1.0k

Countries citing papers authored by Charlene Wu

Since Specialization
Citations

This map shows the geographic impact of Charlene Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charlene Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charlene Wu more than expected).

Fields of papers citing papers by Charlene Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charlene Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charlene Wu. The network helps show where Charlene Wu may publish in the future.

Co-authorship network of co-authors of Charlene Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Charlene Wu. A scholar is included among the top collaborators of Charlene Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charlene Wu. Charlene Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chien, Jien‐Wen, Charlene Wu, & Chang‐Chuan Chan. (2022). The association of hypertension and prehypertension with greenness and PM2.5 in urban environment. The Science of The Total Environment. 821. 153526–153526. 16 indexed citations
2.
Lin, Chien‐Yu, Hui‐Ling Lee, Charlene Wu, et al.. (2021). Global DNA methylation mediates the association between urine mono-2-ethylhexyl phthalate and serum apoptotic microparticles in a young Taiwanese population. The Science of The Total Environment. 808. 152054–152054. 6 indexed citations
3.
Lin, Chien‐Yu, Hui‐Ling Lee, Yi‐Ting Hwang, et al.. (2020). Urinary heavy metals, DNA methylation, and subclinical atherosclerosis. Ecotoxicology and Environmental Safety. 204. 111039–111039. 28 indexed citations
4.
Lin, Chien‐Yu, Po‐Chin Huang, Charlene Wu, Fung‐Chang Sung, & Ta‐Chen Su. (2019). Association between urine lead levels and cardiovascular disease risk factors, carotid intima-media thickness and metabolic syndrome in adolescents and young adults. International Journal of Hygiene and Environmental Health. 223(1). 248–255. 30 indexed citations
5.
Su, Ta‐Chen, Jing-Shiang Hwang, Pao‐Ling Torng, et al.. (2019). Phthalate exposure increases subclinical atherosclerosis in young population. Environmental Pollution. 250. 586–593. 53 indexed citations
7.
Wu, Charlene, et al.. (2016). Pharmacokinetics and bioavailability of oral single-dose maleic acid in biofluids of Sprague-Dawley rats. Drug Metabolism and Pharmacokinetics. 31(6). 451–457. 6 indexed citations
8.
9.
Chen, Hsin‐Chang, et al.. (2015). Study of urinary 2-{[2-(acetylamino-2-carboxyethyl]sulfanyl}butanedioic acid, a mercapturic acid of rats treated with maleic acid. Toxicology Letters. 236(3). 131–137. 3 indexed citations
11.
Evans, Karen A., Dwight M. Morrow, Harvey E. Fries, et al.. (2010). 3-Urea-1-(phenylmethyl)-pyridones as novel, potent, and selective EP3 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 20(22). 6744–6747. 6 indexed citations
12.
Hilfiker, Mark A., Ning Wang, Zhimin Du, et al.. (2009). Discovery of novel aminothiadiazole amides as selective EP3 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 19(15). 4292–4295. 15 indexed citations
13.
Wu, Charlene, et al.. (2009). The assessment of cell cycle genes in the rat mandibular condyle. Archives of Oral Biology. 54(5). 470–478. 2 indexed citations
14.
Su, Xin, Lisa A. Leon, Charlene Wu, et al.. (2008). Modulation of bladder function by prostaglandin EP 3 receptors in the central nervous system. American Journal of Physiology-Renal Physiology. 295(4). F984–F994. 32 indexed citations
15.
Behm, David J., et al.. (2008). Epoxyeicosatrienoic Acids Function as Selective, Endogenous Antagonists of Native Thromboxane Receptors: Identification of a Novel Mechanism of Vasodilation. Journal of Pharmacology and Experimental Therapeutics. 328(1). 231–239. 84 indexed citations
16.
McCafferty, Gerald P., Mark Pullen, Charlene Wu, et al.. (2007). Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 293(1). R299–R305. 22 indexed citations
18.
Massa, Paul T., et al.. (2004). Dysmyelination and reduced myelin basic protein gene expression by oligodendrocytes of SHP‐1‐deficient mice. Journal of Neuroscience Research. 77(1). 15–25. 30 indexed citations
19.
20.
Massa, Paul T. & Charlene Wu. (1998). Increased Inducible Activation of NF-κB and Responsive Genes in Astrocytes Deficient in the Protein Tyrosine Phosphatase SHP-1. Journal of Interferon & Cytokine Research. 18(7). 499–507. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026